Results 211 to 220 of about 126,819 (310)

BSAVA Petsavers Article: Validation of an ELISA assay for measurement of the metabolite of serotonin, 5‐hydroxyindole acetic acid (5‐HIAA), in canine urine

open access: yesJournal of Small Animal Practice, EarlyView.
Objectives Serotonin (5‐hydroxytryptophan), implicated in a number of canine diseases, has a very short half‐life in the serum. Urine concentration of its breakdown product 5‐hydroxyindole acetic acid after an 8 hour fast is a more reliable measure of circulating serotonin in humans.
D. Castillo   +3 more
wiley   +1 more source

‘BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026

open access: yes
BJU International, EarlyView.
Vignesh T. Packiam   +10 more
wiley   +1 more source

Clinical benefit of faecal microbiota transplantation administered via a single retention enema as an adjunctive treatment in dogs with chronic enteropathy: a randomised controlled trial

open access: yesJournal of Small Animal Practice, EarlyView.
Objectives To evaluate the clinical benefit of faecal microbiota transplantation administered via a single retention enema, as an adjunctive treatment in the management of dogs with chronic enteropathy. Materials and Methods Blinded, randomised controlled trial.
F. Allerton   +16 more
wiley   +1 more source

Urothelial Bladder Cancer With Cardiac Metastasis: A Case Report. [PDF]

open access: yesCureus
Bounouar O   +4 more
europepmc   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

open access: yesVeterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy